Skip to content
Screener

BioCryst Pharmaceuticals BCRX License and other revenues — Receivables

Similar metrics at other companies

Granite Construction logo
GVAOther — Receivables
$70.85M-19.0%
Albany International Inc. logo
AINAlbany Engineered Composites — Receivables
$57.1M-22.8%
Granite Construction logo
GVAContracts completed and in progress: — Receivables
$482.71M+42.5%
Granite Construction logo
GVAMaterials sales — Receivables
$84.53M+84.2%
NVR logo
NVRHome Building Segment — Receivables
$49.64M+19.6%
Williams Companies logo
WMBOther Receivable — Receivables, Net, Current
$75M+44.2%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.51B+46.1%
Enterprise value$2.77B+46.6%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.

The source filing: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:03 PM EST
Fiscal year
FY2025
Accession
0001628280-26-012240

At December 31, 2025 and 2024, receivables related to license and other revenue were $3,976 and $2,223, respectively.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is BioCryst Pharmaceuticals's license and other revenues — receivables?
BioCryst Pharmaceuticals (BCRX) reported license and other revenues — receivables of $3.98M in Q4 2025.
What does license and other revenues — receivables mean?
This metric captures the aggregate balance of accounts receivable specifically attributable to the licensing and other revenue segment. It reflects the timing difference between the recognition of revenue from contractual milestones or royalties and the actual receipt of cash. Analyzing this balance is essential for evaluating the cash conversion cycle and the credit quality of the company's licensing partners.

Ask your AI about BioCryst Pharmaceuticals's license and other revenues — receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude